In support of this concept, we previously reported decreased levels of beta hydroxybutyrate in mice with lung cancer induced cachexia, and significant anti-cachectic benefits when ketogenesis was restored with the PPARα agonist, fenofibrate (5). The gene discussed is PPARA; the disease is lung carcinoma.